TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30672067

Group type: EXPERIMENTAL
Intervention: IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: IVIG restabilization
Number of subjects: 245

Group type: COMPARATOR
Intervention: IVIG withdrawal
Number of subjects: 245
Study: 27687805

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Posterior Approach (PA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (DAA and PA)
Number of subjects: 72
Study: 27399131

Group type: EXPERIMENTAL
Intervention: Dual therapy (ticagrelor and apixaban)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triple therapy (ticagrelor and apixaban with acetylsalicylic acid)
Number of subjects: 40
Study: 24288164

Group type: EXPERIMENTAL
Intervention: Positive condition (candidates presented with reference to their strengths)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard condition (candidates presented by referring to the disability they presented)
Number of subjects: 80
Study: 23082133

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pravastatin (20 mg daily)
Number of subjects: 37
Study: 20715300

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30‐45 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17383923

Group type: EXPERIMENTAL
Intervention: Total dorsal ramus block
Number of subjects: 14

Group type: COMPARATOR
Intervention: Trigger point injection
Number of subjects: 14
Study: 16264159

Group type: EXPERIMENTAL
Intervention: Single-visit program (n = 1716)
Number of subjects: 3521

Group type: COMPARATOR
Intervention: Usual care (n = 1805)
Number of subjects: 3521
Study: 12416546

Group type: EXPERIMENTAL
Intervention: Local chemotherapy with cisplatin-depot (CDDP-D)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Subtotal tumor ablation without CDDP-D implantation (Control Group B)
Number of subjects: 38
Study: 10451136

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg x kg(‐1) p.o. 30 min before anesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 60
Study: 7784720

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (5 mg)
Number of subjects: 536
Study: 1315346

Group type: COMPARATOR
Intervention: NaF rinse (12 mmol/L)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Two-solution F rinse (12 mmol/L)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (pH 7 remineralizing solution)
Number of subjects: 51
Study: 4062049

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) load (920 calories)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31281343

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29302655

Group type: EXPERIMENTAL
Intervention: Phlebotomy for iron reduction
Number of subjects: 1277
Study: 26476267

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral-Based Physical Therapy (CBPT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Education program
Number of subjects: 86
Study: 26577091

Group type: EXPERIMENTAL
Intervention: Primary care practice support (comprehensive evidence-based quality improvement strategy involving practice facilitation, academic detailing, technology support, and regional learning collaboratives)
Number of subjects: 900000

Group type: EXPERIMENTAL
Intervention: Primary care practice support
Number of subjects: 900000
Study: 23730856

Group type: EXPERIMENTAL
Intervention: Community-based stroke nursing intervention (three 2-hour sessions per week for 8 weeks)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Community-based stroke nursing intervention
Number of subjects: 127

Group type: COMPARATOR
Intervention: Normal care group (general stroke education programme)
Number of subjects: 127
Study: 21156862

Group type: EXPERIMENTAL
Intervention: Difference mind-set priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mentalizing about out-group targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Communication with interaction partners of different minimal-group membership
Number of subjects: 0
Study: 18815727

Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg - Caffeine 130 mg (PCF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (NAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study: 16807444

Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 1 h infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 2 h infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gemcitabine 300 mg/m(2) administered during 3 h infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m(2) administered during 30 min infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 12669262

Group type: EXPERIMENTAL
Intervention: Creatine-pyruvate (Cr(pyr), 2 x 3.5 g x d‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Creatine-pyruvate (Cr(pyr))
Number of subjects: 14
Study: 11854983

Group type: EXPERIMENTAL
Intervention: Progressive relaxation intervention (7-muscle group), home practice with audiocassette tapes and diaries
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (30 minutes of relaxation)
Number of subjects: 43
Study: 9104521

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Double burst stimulation 3.3 (DBS3.3)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Double burst stimulation 3.2 (DBS3.2)
Number of subjects: 130
Study: 7960690

Group type: EXPERIMENTAL
Intervention: Moderate exercise training (45 min, 3 times weekly for 12 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continued exercise at varying levels at home during 1 year of follow-up
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no change in lifestyle)
Number of subjects: 40
Study: 2884861

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dosage 6.9 mg, range 1 to 16)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (mean dosage 84.6 mg, range 25 to 100)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 104
Study: 29803985

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study: 27160933

Group type: EXPERIMENTAL
Intervention: Bioxtra® toothpaste with salivary enzymes, essential oils, proteins and colostrum extract
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fluoride toothpaste without menthol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bioxtra® toothpaste
Number of subjects: 64
Study: 25359394

Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (Zilver® PTX®)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Bare metal stent (Misago® RX)
Number of subjects: 186
Study: 21900842

Group type: EXPERIMENTAL
Intervention: 12 kcal·kg⁻¹·wk⁻¹ exercise training at 50% of aerobic capacity
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 419
Study: 20733211

Group type: EXPERIMENTAL
Intervention: Priming condition (scrambled sentence task)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Skill-focused condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Positive priming condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neutral priming condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Negative priming condition
Number of subjects: 64
Study: 17593858

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine and 1.0% lidocaine (ropi‐lido group; n=146)
Number of subjects: 287

Group type: COMPARATOR
Intervention: 1.0% lidocaine alone (placebo‐lido group; n=141)
Number of subjects: 287
Study: 15716697

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 124
Study: 12237201

Group type: EXPERIMENTAL
Intervention: Magnesium-lignocaine (20% magnesium sulphate 500 mg + lignocaine 1% 75 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lignocaine alone (1% 75 mg)
Number of subjects: 49
Study: 8009327

Group type: EXPERIMENTAL
Intervention: Functional restoration treatment at two clinics
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group (no functional restoration treatment)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Functional restoration treatment
Number of subjects: 542
Study: 3191660

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study: 31172940

Group type: EXPERIMENTAL
Intervention: UOVO rehabilitation tool
Number of subjects: 1
Study: 28296471

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy with mucosal biopsies
Number of subjects: 278
Study: 26087107

Group type: EXPERIMENTAL
Intervention: Hange-Shashin-To (HST) 5.0 g mixed with jelly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (jelly only)
Number of subjects: 0
Study: 23618760

Group type: EXPERIMENTAL
Intervention: VSL#3 (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Number of subjects: 229
Study: 21747089

Group type: EXPERIMENTAL
Intervention: MMR-D tumors
Number of subjects: 1852

Group type: COMPARATOR
Intervention: MMR intact tumors with 18q intact
Number of subjects: 1852
Study: 19164269

Group type: EXPERIMENTAL
Intervention: Exercise alone (EX)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise combined with moderate caloric restriction (EX + CR)
Number of subjects: 24
Study: 16778264

Group type: EXPERIMENTAL
Intervention: Budesonide (200 mcg qd for children < 11 years old and 400 mcg qd for others)
Number of subjects: 7165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7165
Study: 15117980

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously (i.v.) day 1 with vitamin B12, folic acid, and dexamethasone
Number of subjects: 571

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² i.v. day 1 with dexamethasone
Number of subjects: 571
Study: 11881188

Group type: EXPERIMENTAL
Intervention: Amixine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9623901

Group type: EXPERIMENTAL
Intervention: Bioerodible tetracycline gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 18
Study: 8188838

Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis material
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metal pin fixation
Number of subjects: 50
Study: 2492674

Group type: EXPERIMENTAL
Intervention: 150 micrograms levo-thyroxine (LT4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of 100 micrograms LT4 and 100 micrograms iodide
Number of subjects: 20
Study: 824567

Group type: EXPERIMENTAL
Intervention: Eterobarb
Number of subjects: 27

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 27
Study: 31260374

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Viremia
Number of subjects: 1759
Study: 28592515

Group type: EXPERIMENTAL
Intervention: Lysine (5 or 10 g l-lysine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 12
Study: 26010632

Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplement (100 mg of total isoflavones, n=193)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo (n=193)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplement
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 23495124

Group type: EXPERIMENTAL
Intervention: TAU + BTB
Number of subjects: 58

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 58
Study: 21900836

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 IV, gemcitabine 1500 mg/m2 IV, and bevacizumab 10 mg/kg IV (days 1 and 15 of 28‐day cycles)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 IV, carboplatin AUC=5 IV, and bevacizumab 15 mg/kg IV (day 1 of 21‐day cycles)
Number of subjects: 110
Study: 19328723

Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest after angiography
Number of subjects: 195

Group type: COMPARATOR
Intervention: 4 hours of bed rest after angiography
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Single-arm 2-hour bed rest trial
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Overall procedures
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Patients with platelet counts < 100 x 10(9)/L
Number of subjects: 195
Study: 17662568

Group type: EXPERIMENTAL
Intervention: Lay educators in asthma self-management programme
Number of subjects: 8
Study: 15166883

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Senile dementia of Alzheimer type (SDAT) patients
Number of subjects: 56

Group type: COMPARATOR
Intervention: Other types of dementia patients
Number of subjects: 56
Study: 11668655

Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) with spatial filtering technique
Number of subjects: 15
Study: 9630024

Group type: EXPERIMENTAL
Intervention: Static exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dynamic exercise
Number of subjects: 11
Study: 8202906

Group type: EXPERIMENTAL
Intervention: Oilseed rape area
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Non-oilseed rape area
Number of subjects: 2000
Study: 2720578

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate preparation (MS Contin tablets) administered every 12 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Morphine oral solution (MOS) administered every 4 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both MSC and MOS
Number of subjects: 17
Study: 31911074

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise (IAE) for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 29745627

Group type: EXPERIMENTAL
Intervention: Blindfolded balance training (BBT) for two weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physical therapy (PT) for two weeks
Number of subjects: 16
Study: 28583242

Group type: EXPERIMENTAL
Intervention: Hand files
Number of subjects: 110

Group type: COMPARATOR
Intervention: Revo‐S rotary instruments
Number of subjects: 110
Study: 25123562

Group type: EXPERIMENTAL
Intervention: Risedronate and elcatonin (combined group, n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Risedronate alone (risedronate group, n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (risedronate and elcatonin; risedronate alone)
Number of subjects: 45
Study: 24204744

Group type: EXPERIMENTAL
Intervention: MEDI‐559 (live attenuated intranasal vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21914136

Group type: EXPERIMENTAL
Intervention: Tadalafil (40 mg for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 28
Study: 19916693

Group type: EXPERIMENTAL
Intervention: Immobilization in external rotation (ER)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Immobilization in internal rotation (IR)
Number of subjects: 55
Study: 16407639

Group type: EXPERIMENTAL
Intervention: 400 mg oral sustained‐release theophylline plus budesonide (200 microg b.i.d.)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg montelukast plus budesonide (200 microg b.i.d.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Double dose of inhaled budesonide (400 microg b.i.d.)
Number of subjects: 90
Study: 14525750

Group type: EXPERIMENTAL
Intervention: Computerized ED discharge instructions with National Highway Traffic Safety Administration recommendations for motor vehicle CRDs
Number of subjects: 110

Group type: COMPARATOR
Intervention: CDIs without the recommendations
Number of subjects: 110
Study: 10601787

Group type: EXPERIMENTAL
Intervention: Cervitec varnish (1% chlorhexidine and 1% thymol)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fluoride varnishes (Fluor Protector and Duraphat)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Thymol varnish
Number of subjects: 65
Study: 9170417

Group type: EXPERIMENTAL
Intervention: Acute febrile infection (HIV-seropositive patients with pneumonia)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acute myeloid leukemia with afebrile neutropenia from chemotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Persistent neutropenia (HIV-seropositive individuals)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pneumonia (HIV-seronegative patients)
Number of subjects: 45
Study: 1439640

Group type: EXPERIMENTAL
Intervention: Intraaortic protamine administration (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous protamine administration (group V)
Number of subjects: 32
Study: 2432555

Group type: EXPERIMENTAL
Intervention: Auto increment pacing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Auto burst pacing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Random burst pacing
Number of subjects: 32

Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 32
Study: 31615996

Group type: EXPERIMENTAL
Intervention: Low dose carbon monoxide exposure (100-200 ppm) for 12 weeks
Number of subjects: 38
Study: 30360964

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W (80 mg subcutaneous every two weeks)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W (80 mg subcutaneous every four weeks)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg Q2W)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 27502810

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan (TJQ) intervention (2/week for 16 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Educational course about FMS (Control Group) (2/week for 16 weeks)
Number of subjects: 44
Study: 24452879

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone prolonged-release (PR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone PR
Number of subjects: 0
Study: 22582911

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) plus red light therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo plus red light therapy
Number of subjects: 38
Study: 20974573

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17155971

Group type: EXPERIMENTAL
Intervention: Routine interval computed tomography (CT)
Number of subjects: 105
Study: 15578800

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N of 1 randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Academic medicine
Number of subjects: 0
Study: 11856461

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma (SDP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 67
Study: 9536834

Group type: EXPERIMENTAL
Intervention: Conventional management supplemented by regular measurements of static respiratory system compliance
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional clinical management (control group)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group survivors
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Experimental group survivors
Number of subjects: 245
Study: 7633189

Group type: EXPERIMENTAL
Intervention: 0.35 mg kg‐1 day‐1 prednisolone for six months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 41
Study: 1688515

Group type: EXPERIMENTAL
Intervention: ThioTEPA (30 mg) in distilled water
Number of subjects: 8

Group type: COMPARATOR
Intervention: ThioTEPA (30 mg) in 10% (v/v) Tween 80 (30 ml)
Number of subjects: 8
Study: 28071

Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol (160 mg b.i.d.)
Number of subjects: 20
Study: 30381466

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Altruistic messages
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Dashboard access
Number of subjects: 1178

Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 1178
Study: 28135843

Group type: EXPERIMENTAL
Intervention: Contingency management intervention using ethyl glucuronide (EtG) biomarker
Number of subjects: 79

Group type: COMPARATOR
Intervention: Reinforcement only for study participation (Control)
Number of subjects: 79
Study: 25484179

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800-2400mg, once-daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 600-1800mg, once-daily
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 900mg, once-daily (during recurrence prevention study)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 300, 900, and 1800mg, once-daily (during recurrence prevention study)
Number of subjects: 283
Study: 22689216

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlisted Control Group
Number of subjects: 0
Study: 21164424

Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time <12 h
Number of subjects: 10464

Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time 12 to 24 h
Number of subjects: 10464

Group type: EXPERIMENTAL
Intervention: Breast-feeding initiation time >24 h
Number of subjects: 10464